THC Biomed International Ltd. (OTCMKTS:THCBF) has obtained an order from Germany to export Dried Marihuana. The company has commenced the process to fulfill regulatory guidelines to export to the EU. It is thrilled to commence to claw into, what is expected to be over a billion-dollar Global Cannabis Market.
The details
THC Biomed presently provides 29 distinct Genetic strains for sale and boasts the largest variety of Genetic strains accessible in Canada to home cultivators. John Miller, the CEO and President, said that the company plans to soon commence selling dried Marihuana as a provisional supply to listed home cultivators at $4.20 per gram. They consider this would mark as the lowest price ever presented to medical patients in Canada.
Miller added that they are delighted to provide this wholesale-type pricing to their fellow cultivators. The home growing industry is projected to expand rapidly in the case recreational Marihuana is launched.
THC announced that Dr. Ashish Dave has given his consent to join the Board. He was engaged as a Director last week. Dr. Dave is a famous scientist who has earlier consulted for company. Dr. Dave has a Master’s Degree in botany and PHD in crop tissue culture. THC Biomed has settled debt obligations of $58,596 for consulting services via the issuance of as many as 133,172 common stock of THC at a considered price of $0.44 a share.
THC Biomed is an authorized LP of dried Marihuana for medical uses and fresh Cannabis and Marihuana oil, production only. The company’s objective is to be on the pioneering edge of scientific research and advancement of services and products linked to the medicinal cannabis industry while achieving a standard of excellence.
In the last trading session, the stock price of THC Biomed declined more than 3% to close the day at $0.326.